Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive review of 4,000 liver cancer patients aims to uncover regional trends

NCT ID NCT07650773

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study will collect and analyze medical records from about 4,000 adults diagnosed with liver cancer (hepatocellular carcinoma) in Middle Eastern and North African countries between 2015 and 2023. Researchers want to understand what causes the cancer, how it is treated, and what outcomes patients have. No new treatments or procedures are given; the goal is to learn from existing data to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 4,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Data from patients' medical charts will be gathered from 3 to 5 tertiary referral centers per country across 10 countries in the MENA region, including Egypt, KSA, the United Emirates, Lebanon, Kuwait, Qatar, Iraq, Morocco, Jordan, and Turkey. The study population comprises patients diagnosed with HCC between January 1, 2015, and December 31, 2023, across these participating centers.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with a radiological or histopathological confirmed diagnosis with HCC in any stage of the tumor between 1st January 2015 and 31st December 2023 (defined as index date). * Patient or next of kin/legal representative (for deceased patients at study entry, unless a waiver is granted) willing and able to provide written informed consent according to the local regulations * Age 18 years or older, and a lawful adult in the country at the index date * Patients with medical records, including etiology, laboratories, radiological, and treatment details will be collected from the participating sites. * Patients with medical records covering at least a 6-month follow-up period, defined as the time from the index date (the date of the first diagnosis) to the earliest of the following: the patient's death, the last medical record entry, or the data extraction date. Additionally, patients who died within this 6-month period will also be included. Exclusion Criteria: * Patients with other cancer diagnosis on or before index date. * Patients with records missing information on etiology, laboratory results, radiological findings, or treatment details (≥30% of key variables). * Previously opted out of sharing medical records * Patients participating in clinical trials * Pregnant patient

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    17 sites in 7 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    NOT_YET_RECRUITING

    Al Mansurah, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Dakahlia, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Damietta, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Menouf, Egypt

  • Research Site

    NOT_YET_RECRUITING

    Kuwait City, Kuwait

  • Research Site

    NOT_YET_RECRUITING

    Rabat, Morocco

  • Research Site

    NOT_YET_RECRUITING

    Doha, Qatar

  • Research Site

    NOT_YET_RECRUITING

    Dammam, Saudi Arabia

  • Research Site

    NOT_YET_RECRUITING

    Jeddah, Saudi Arabia

  • Research Site

    NOT_YET_RECRUITING

    Mecca, Saudi Arabia

  • Research Site

    NOT_YET_RECRUITING

    Riyadh, Saudi Arabia

  • Research Site

    NOT_YET_RECRUITING

    Ankara, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Erzurum, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Istanbul, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Izmir, Turkey (Türkiye)

  • Research Site

    NOT_YET_RECRUITING

    Abu Dhabi, United Arab Emirates

  • Research Site

    RECRUITING

    Al Ain City, United Arab Emirates

More trials for these conditions

Other studies related to the condition(s) this trial covers.